Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1972 Target Snapshot

Glutamate receptor ionotropic, NMDA 2A · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
148Compounds
26Assays
0Approved Drugs
154.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-15

Glutamate receptor ionotropic, NMDA 2A shows approved-linked disease relevance led by allergic disease. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q12879. Start with allergic disease, then reuse UniProt Q12879 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with allergic disease, then reuse UniProt Q12879 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-15 1 linked drug
Open source guide
Disease program
allergic disease

Glutamate receptor ionotropic, NMDA 2A shows approved-linked disease relevance led by allergic disease. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with allergic disease because it currently carries approved-linked support. Linked drugs include DEXTROMETHORPHAN HYDROBROMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glutamate receptor ionotropic, NMDA 2A as ChEMBL target CHEMBL1972, mapped to UniProt Q12879. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glutamate receptor ionotropic, NMDA 2A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-15
ChEMBL target ID
CHEMBL1972
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-15
www.ebi.ac.uk
UniProt accession
Q12879
Glutamate receptor ionotropic, NMDA 2A
UniProt accession via ChEMBL component mapping As of 2026-09-15
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-15
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Glutamate receptor ionotropic, NMDA 2A is the right protein anchor across sources, using UniProt Q12879 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why allergic disease is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameGlutamate receptor ionotropic, NMDA 2A
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ12879
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGlutamate receptor ionotropic, NMDA 2A
UniProt AccessionQ12879
Component TypeProtein
Sequence Length1464 aa

Glutamate receptor ionotropic, NMDA 2A

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Glutamate receptor ionotropic, NMDA 2A, mapped to UniProt Q12879. Sequence length is 1464 aa.

Mapped IDQ12879
Review nameGlutamate receptor ionotropic, NMDA 2A
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Glutamate receptor ionotropic, NMDA 2A shows approved-linked disease relevance led by allergic disease. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
allergic disease
1 linked drug · 1 direct · 1 efficacy
Linked drugDEXTROMETHORPHAN HYDROBROMIDE
Approved-linked Approved
common cold
1 linked drug · 1 direct · 1 efficacy
Linked drugDEXTROMETHORPHAN HYDROBROMIDE
Approved-linked Approved
Cough
1 linked drug · 1 direct · 1 efficacy
Linked drugDEXTROMETHORPHAN HYDROBROMIDE
Approved-linked Approved
Fever
1 linked drug · 1 direct · 1 efficacy
Linked drugDEXTROMETHORPHAN HYDROBROMIDE
Approved-linked Approved
Headache
1 linked drug · 1 direct · 1 efficacy
Linked drugDEXTROMETHORPHAN HYDROBROMIDE
Approved-linked Approved
Nasal congestion
1 linked drug · 1 direct · 1 efficacy
Linked drugDEXTROMETHORPHAN HYDROBROMIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with allergic disease because it currently carries approved-linked support. Linked drugs include DEXTROMETHORPHAN HYDROBROMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseallergic disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Phase II
Assay Mix

Activity Type Distribution

IC5084.0
EC5070.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4450420 8.1 IC50 7.9 Preclinical
CHEMBL5171984 7.96 EC50 11.0 Preclinical
CHEMBL4555447 7.57 IC50 27.0 Preclinical
CHEMBL284237 7.54 IC50 29.0 Clinical
CHEMBL5180445 7.41 EC50 39.0 Preclinical
CHEMBL2333945 6.96 IC50 109.0 Preclinical
CHEMBL5272286 6.96 EC50 110.0 Preclinical
CHEMBL5266998 6.82 EC50 150.0 Preclinical
CHEMBL5092058 6.29 EC50 510.0 Preclinical
CHEMBL5794512 6.26 EC50 550.0 Preclinical
Distribution

pChEMBL Value Distribution

6
5.0
6
5.5
4
6.0
7
6.5
1
7.0
3
7.5
1
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

26
Total Assays
36
Tested Compounds
2
Assay Types
Binding — 23 assays, 36 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 14 31 5.6
single protein format 8 4 7.2
assay format 1 1 5.6
Functional — 3 assays, 10 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 3 10 4.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine